Movie
Story
Daiichi Sankyo RD Novare, a technology-led company
that is the driving force behind new drug discoveries.
As a new challenge, the Clinical Research Laboratory
has committed to accelerating oncology research and development.
Representative Director
徳井 太郎
TOKUI TARO
The ardent desire of all Daiichi Sankyo RD Novare employees
is to make as many patients smile as we can with our technologies.
Our objective is to create drugs that are really effective
for each and every patient.
To do so, we initiated a challenge
to transform the drug discovery process.
The application of knowledge and technologies
developed in nonclinical research to the analysis of
clinical specimens will lead to an accurate understanding
of the mechanisms of disease occurring in humans
and lead to the discovery of new drugs.
In the future, we aim to become a leading player
in the drug discovery ecosystem by analyzing
cancer clinical samples in collaboration with
multiple clinical institutions.
Advantages
The laboratory went into full operation in April 2019.
We introduced state-of-the-art technologies and equipment, and ensured
the reliability of data and information through the organizational operation
of GCP compliance.
Vice President
長澤 康男
NAGASAWA YASUO
The main axis of the lab is genomics.
Multilayered and precise analysis is being achieved
by conducting research in conjunction with informatics,
molecular pathology, and genomics.
In addition, we are focusing on the construction of
sophisticated IT systems that ensure security
and the establishment of a system for quality assurance.
We believe it is possible to ensure the reliability of laboratories
by properly processing the complex and vast amounts of
human genome information and by handling it safely
in accordance with the Personal Information Protection Law.
centered on genomics
Platforms
Molecular pathology
Analyze what is happening at the lesion site
Molecular Pathology Group
Senior Researcher
小林 真季
KOBAYASHI MAKI
In molecular pathology, we perform highly precise clinical research
by correctly handling clinical specimens and identifying lesions
based on histopathological knowledge.
By visualizing the changes in expression
and by localizing target molecules,
we analyze what happens at the lesion site.
Visualizing expression changes and localizing target molecules
Genetic analysis
Analyze gene expression and genetic mutations
in collaboration with molecular pathology
Genomics Group
Scientist
大島 慶子
OSHIMA KEIKO
Genetic analysis involves analyzing gene expression and mutations
in conjunction with molecular pathology.
For example, we improve our understanding of the effects
and side effects of drugs by analyzing cancer tissues
and the microenvironment surrounding the cancer tissues,
and by performing correlative analyses
between histopathology and gene expression.
Bioinformatics Group
Senior Director
岡本 敦之
OKAMOTO ATSUSHI
Genomic analysis of clinical samples is also
the ultimate analysis of personal information.
Therefore, we have constructed a rigorous and robust system
to accurately track samples and manage data.
Informatics/Genomics
Understand diseases mechanism and
generate hypotheses by genomic analysis
Genomics Group
Senior Director
和田 直也
WADA NAOYA
On the basis of this robust and secure analysis environment,
we are working to understand diseases at the genome
and even the epigenome level by using a variety of
genomics analysis techniques and
sophisticated informatics techniques
with appropriate processing of specimens.
The Clinical Research Laboratory,
Accelerating Oncology R&D
The Clinical Research Laboratory of Daiichi Sankyo RD Novare,
which took a major step with the vision of leading clinical research
in the field of cancer in Japan.
The ultimate goal is the realization of a world
in which we can rapidly deliver optimal drugs to each and every patient
in need of a new drug.
